CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $6.35 billion. The enterprise value is $5.28 billion.

Market Cap	6.35B
Enterprise Value	5.28B

Important Dates

The next estimated earnings date is Friday, August 7, 2026, before market open.

Earnings Date	Aug 7, 2026
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 88.20 million shares outstanding. The number of shares has increased by 13.77% in one year.

Current Share Class	88.20M
Shares Outstanding	88.20M
Shares Change (YoY)	+13.77%
Shares Change (QoQ)	+5.56%
Owned by Insiders (%)	0.93%
Owned by Institutions (%)	91.41%
Float	65.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,251.64
Forward PS	618.95
PB Ratio	5.80
P/TBV Ratio	5.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,040.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 31.30, with a Debt / Equity ratio of 0.01.

Current Ratio	31.30
Quick Ratio	30.60
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -20.79% and return on invested capital (ROIC) is -14.89%.

Return on Equity (ROE)	-20.79%
Return on Assets (ROA)	-14.42%
Return on Invested Capital (ROIC)	-14.89%
Return on Capital Employed (ROCE)	-19.54%
Weighted Average Cost of Capital (WACC)	5.94%
Revenue Per Employee	$35,711
Profits Per Employee	-$1.32M
Employee Count	142
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +176.13% in the last 52 weeks. The beta is 0.31, so CG Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	+176.13%
50-Day Moving Average	64.57
200-Day Moving Average	52.80
Relative Strength Index (RSI)	68.39
Average Volume (20 Days)	1,241,692

Short Selling Information

The latest short interest is 10.56 million, so 11.97% of the outstanding shares have been sold short.

Short Interest	10.56M
Short Previous Month	9.81M
Short % of Shares Out	11.97%
Short % of Float	16.04%
Short Ratio (days to cover)	11.03

Income Statement

In the last 12 months, CG Oncology had revenue of $5.07 million and -$186.75 million in losses. Loss per share was -$2.35.

Revenue	5.07M
Gross Profit	-135.44M
Operating Income	-214.96M
Pretax Income	-186.75M
Net Income	-186.75M
EBITDA	-212.70M
EBIT	-214.96M
Loss Per Share	-$2.35

Full Income Statement

Balance Sheet

The company has $1.08 billion in cash and $7.58 million in debt, giving a net cash position of $1.07 billion or $12.12 per share.

Cash & Cash Equivalents	1.08B
Total Debt	7.58M
Net Cash	1.07B
Net Cash Per Share	$12.12
Equity (Book Value)	1.09B
Book Value Per Share	12.41
Working Capital	1.07B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$160.01 million and capital expenditures -$422,000, giving a free cash flow of -$160.43 million.

Operating Cash Flow	-160.01M
Capital Expenditures	-422,000
Depreciation & Amortization	2.26M
Net Borrowing	n/a
Free Cash Flow	-160.43M
FCF Per Share	-$1.82

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,238.99%
Pretax Margin	-3,682.61%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.77%
Shareholder Yield	-13.77%
Earnings Yield	-2.94%
FCF Yield	-2.53%

Analyst Forecast

The average price target for CG Oncology is $90.29, which is 25.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$90.29
Price Target Difference	25.47%
Analyst Consensus	Strong Buy
Analyst Count	16
Revenue Growth Forecast (3Y)	383.93%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 41.08 and a Piotroski F-Score of 4.

Altman Z-Score	41.08
Piotroski F-Score	4